Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 2
1956 1
1957 1
1960 1
1961 2
1962 1
1963 1
1964 2
1965 2
1966 4
1967 5
1968 12
1969 18
1970 6
1971 9
1972 21
1973 21
1974 24
1975 21
1976 31
1977 25
1978 26
1979 25
1980 32
1981 43
1982 39
1983 51
1984 55
1985 82
1986 58
1987 68
1988 53
1989 83
1990 57
1991 56
1992 55
1993 49
1994 45
1995 42
1996 37
1997 20
1998 41
1999 36
2000 30
2001 33
2002 33
2003 32
2004 27
2005 37
2006 24
2007 30
2008 29
2009 28
2010 33
2011 37
2012 38
2013 38
2014 45
2015 50
2016 48
2017 36
2018 36
2019 51
2020 46
2021 62
2022 45
2023 51
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

2,092 results

Results by year

Filters applied: . Clear all
Page 1
Pseudoleukocoria.
Kawashima Y, Adachi A. Kawashima Y, et al. Pediatr Int. 2023 Jan-Dec;65(1):e15600. doi: 10.1111/ped.15600. Pediatr Int. 2023. PMID: 37515354 No abstract available.
1-Oleoyl-lysophosphatidylethanolamine stimulates RORγt activity in TH17 cells.
Endo Y, Kanno T, Nakajima T, Ikeda K, Taketomi Y, Yokoyama S, Sasamoto S, Asou HK, Miyako K, Hasegawa Y, Kawashima Y, Ohara O, Murakami M, Nakayama T. Endo Y, et al. Among authors: kawashima y. Sci Immunol. 2023 Aug 4;8(86):eadd4346. doi: 10.1126/sciimmunol.add4346. Epub 2023 Aug 4. Sci Immunol. 2023. PMID: 37540735
Identification of trypsin-degrading commensals in the large intestine.
Li Y, Watanabe E, Kawashima Y, Plichta DR, Wang Z, Ujike M, Ang QY, Wu R, Furuichi M, Takeshita K, Yoshida K, Nishiyama K, Kearney SM, Suda W, Hattori M, Sasajima S, Matsunaga T, Zhang X, Watanabe K, Fujishiro J, Norman JM, Olle B, Matsuyama S, Namkoong H, Uwamino Y, Ishii M, Fukunaga K, Hasegawa N, Ohara O, Xavier RJ, Atarashi K, Honda K. Li Y, et al. Among authors: kawashima y. Nature. 2022 Sep;609(7927):582-589. doi: 10.1038/s41586-022-05181-3. Epub 2022 Sep 7. Nature. 2022. PMID: 36071157 Free PMC article.
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
Okuma Y, Kubota K, Shimokawa M, Hashimoto K, Kawashima Y, Sakamoto T, Wakui H, Murakami S, Okishio K, Hayashihara K, Ohe Y; Tokyo Cooperative Oncology Group (TCOG). Okuma Y, et al. Among authors: kawashima y. JAMA Oncol. 2024 Jan 1;10(1):43-51. doi: 10.1001/jamaoncol.2023.5013. JAMA Oncol. 2024. PMID: 37991747
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Kawashima Y, et al. Lancet Respir Med. 2022 Jan;10(1):72-82. doi: 10.1016/S2213-2600(21)00166-1. Epub 2021 Aug 26. Lancet Respir Med. 2022. PMID: 34454653 Clinical Trial.
Materials chemistry of triplet dynamic nuclear polarization.
Nishimura K, Kouno H, Kawashima Y, Orihashi K, Fujiwara S, Tateishi K, Uesaka T, Kimizuka N, Yanai N. Nishimura K, et al. Among authors: kawashima y. Chem Commun (Camb). 2020 Jul 2;56(53):7217-7232. doi: 10.1039/d0cc02258f. Chem Commun (Camb). 2020. PMID: 32495753 Review.
2,092 results